Premium
Naphthalene Monoimide Derivative Ameliorates Amyloid Burden and Cognitive Decline in a Transgenic Mouse Model of Alzheimer's Disease (Adv. Therap. 4/2021)
Author(s) -
Samanta Sourav,
Rajasekhar Kolla,
Ramesh Madhu,
Murugan Natarajan Arul,
Alam Shadab,
Shah Devanshi,
Clement James Premdas,
Govindaraju Thimmaiah
Publication year - 2021
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.202170007
Subject(s) - genetically modified mouse , transgene , cognitive decline , amyloid (mycology) , disease , neuroscience , cognition , pathological , medicine , dementia , pathology , chemistry , psychology , biochemistry , gene
The aberrant production, aggregation, and accumulation of parenchymal amyloid‐β (Aβ) is the pathological hallmark of multifaceted Alzheimer's disease (AD) etiology and accounts for neuronal loss, progressive memory impairment, and cognitive decline. An aptly designed small molecule (TGR63) effectively reduced amyloid burden in the brain, rescues neuronal cells, and improves memory and cognition in a transgenic AD mouse model. This is reported by Sourav Samanta, Kolla Rajasekhar, Madhu Ramesh, Natarajan Arul Murugan, Shadab Alam, Devanshi Shah, James Premdas Clement, Thimmaiah Govindaraju in article 2000225.